Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC disclosures from Jazz Pharmaceuticals Plc rarely read like light bedtime material. Hundreds of pages cover narcolepsy franchise sales, Irish tax rulings, oncology trial data and more鈥攎aking it tough to pinpoint what really moves JAZZ shares or to get Jazz Pharmaceuticals SEC filings explained simply.
Stock Titan solves this problem with AI-powered analysis. Every Jazz Pharmaceuticals quarterly earnings report 10-Q filing and Jazz Pharmaceuticals annual report 10-K simplified arrives within seconds of hitting EDGAR, already distilled into clear takeaways: segment revenue shifts, R&D burn, and newly added risk factors. AG真人官方-time alerts flag Jazz Pharmaceuticals insider trading Form 4 transactions so you can watch executive moves as they happen.
Key insights you鈥檒l access instantly:
- Phase milestones and licensing deals summarized in Jazz Pharmaceuticals 8-K material events explained.
- Board pay and option grants detailed in the latest Jazz Pharmaceuticals proxy statement executive compensation.
- Comparative analytics for Xywav, Epidiolex, Rylaze and Zepzelca across multiple reporting periods.
- Dashboards of Jazz Pharmaceuticals Form 4 insider transactions real-time鈥攊deal for tracking Jazz Pharmaceuticals executive stock transactions Form 4.
Whether you search 鈥渦nderstanding Jazz Pharmaceuticals SEC documents with AI鈥� or need a quick Jazz Pharmaceuticals earnings report filing analysis, our platform surfaces answers in plain language, saving hours of manual review. Follow every filing type鈥攆rom 10-K to 13G鈥攊n one place and stay ahead of the next clinical catalyst.
Form 4 filing summary for Taylor Morrison Home Corp. (TMHC): Director Christopher J. Yip reported the acquisition of 387 deferred stock units (DSUs) on 06/30/2025. Each DSU is economically equivalent to one share of TMHC common stock and was received under the company鈥檚 Non-Employee Director Deferred Compensation Plan as an election to defer cash retainer and committee fees. The transaction is coded 鈥淎,鈥� signifying an award and not an open-market purchase.
After the transaction, Yip鈥檚 aggregate holding stands at 14,664 DSUs. The units will settle in common shares upon the earlier of (i) 01-Sep-2027, (ii) the director鈥檚 separation from the board, or (iii) a change of control. No common-stock sales or purchases were reported, and no cash price was involved.
The award is relatively small in size and routine in nature, providing limited insights into the company鈥檚 near-term fundamentals or insider sentiment beyond ongoing board-level equity alignment.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
What is the primary focus of Jazz Pharmaceuticals?
How does Jazz Pharmaceuticals generate its revenue?
What distinguishes Jazz Pharmaceuticals in the biopharmaceutical industry?
Which therapeutic areas are highlighted in Jazz Pharmaceuticals' portfolio?
How does Jazz Pharmaceuticals ensure its products meet regulatory standards?
What role does research and development play at Jazz Pharmaceuticals?
